Eli Lilly Acquires Contessa in $47.8B Deal

The blockbuster acquisition aims to bolster Eli Lilly's pharmaceutical dominance.

Apr. 1, 2026 at 10:25pm

Got story updates? Submit your updates here. ›

Eli Lilly and Company, the pharmaceutical giant, has announced a definitive agreement to acquire Contessa, a leading player in the clinical research and drug development space, in a deal valued at $47.8 billion. The move is expected to significantly strengthen Eli Lilly's position in the global pharmaceutical market and accelerate its pipeline of innovative therapies.

Why it matters

This acquisition represents a major strategic move by Eli Lilly to expand its reach and capabilities in the rapidly evolving pharmaceutical industry. By bringing Contessa's expertise in clinical research and drug development under its umbrella, Eli Lilly aims to gain a competitive edge in bringing new and improved treatments to market, solidifying its position as a dominant force in the sector.

The details

The $47.8 billion deal will see Eli Lilly acquire Contessa, a company known for its innovative approaches to clinical trials and drug discovery. The acquisition is expected to enhance Eli Lilly's research and development capabilities, allowing the company to accelerate the development of its pipeline of promising drug candidates. The combined entity will leverage Contessa's cutting-edge technologies and Eli Lilly's extensive resources to drive the next generation of pharmaceutical breakthroughs.

  • Eli Lilly announced the definitive agreement to acquire Contessa on April 1, 2026.

The players

Eli Lilly and Company

A global pharmaceutical company that develops and markets a wide range of medications, including treatments for diabetes, oncology, and neuroscience.

Contessa

A leading clinical research and drug development company known for its innovative approaches to accelerating the drug discovery and approval process.

Got photos? Submit your photos here. ›

What they’re saying

“This acquisition represents a transformative moment for Eli Lilly as we continue to shape the future of the pharmaceutical industry. By combining Contessa's expertise with our own, we will be able to drive even greater innovation and bring life-changing treatments to patients around the world.”

— David Ricks, Chairman and CEO of Eli Lilly

“We are thrilled to be joining forces with Eli Lilly, a company that shares our commitment to advancing medical science and improving patient outcomes. Together, we will be able to accelerate the development of groundbreaking therapies and make a lasting impact on global health.”

— Dr. Emily Walters, CEO of Contessa

What’s next

The acquisition is subject to regulatory approvals and is expected to close by the end of 2026.

The takeaway

This landmark acquisition solidifies Eli Lilly's position as a pharmaceutical powerhouse, positioning the company to drive the next wave of medical innovation and cement its dominance in the global healthcare market.